

**INTERIM REPORT  
for I-III 2021  
Medika d.d. Zagreb**

**April 2021**

## Management interim report

### *Comment on the business results for the first quarter of 2021*

Medika d.d. („Company“) has realised total revenue in the first three months of 2021 in amount of HRK 977.0 million which is by 6.95% lower comparing to the same period of previous year. The epidemic caused by the Covid-19 virus affected on a significant increase in sales in March 2020.

Sales revenues which amount to HRK 972.4 million for the first three months of 2021 are by 6.96% lower comparing to the same period of previous year.

Share of sales revenues in the total revenue is 99.52% while in the same period of previous year it was 99.54%.

Other operating revenues which amount to HRK 3.3 million are lower by 23.74% comparing to the same period of previous year. Share of other operating revenues in total revenue was 0.41% in the first three months of 2020, and in the first three months of 2021 is 0.34%.

Out of the total sales revenues, 99.93% revenues are generated on domestic market, while 0.07% is generated on the foreign market. In the first three months of 2020, 99.72% revenues were generated on domestic market, while 0.28% were generated on the foreign market.

Material expenses amount to HRK 932.4 million and are 6.56% lower comparing to the same period of previous year, which is in accordance with the decrease of sales revenue. Since the operating expenses decrease in higher percentage, share of material expenses in the operating expenses is higher by 0.93 percentage point comparing to the same period of previous year and amounts to 97.11%.

Employee expenses are lower by 8.92% comparing to the same period of previous year. Their share in the total expenses amounts to 1.69% and decreased by 0.03 percentage points compared to the same period last year. This decrease was affected by the average number of employees, which is lower in the first three months of 2021 compared to the same period of the previous year.

Finance income has increased compared to the same period of the previous year for HRK 842 thousand, which is 156.59%. Finance income relates entirely to interest income.

Finance expenses have decreased compared to the same period of previous year by HRK 96 thousand, which is 6.53%. Their share has not changed comparing to the same period of previous year and amounts to 0.14%.

Gross margin in the first three months of 2020 amounted to 5.24%, while in the first three months of 2021 amounts to 4.84%, which is decrease by 0.40 percentage point.

Gross profit (profit before taxation) amounts to HRK 15.6 million, while in the same period of previous year amounted to HRK 11.1 million, which is increase of HRK 4.5 million, or 40.12%. Higher gross profit is result of greater decrease of total expenses (decrease of 7.45% comparing to the same period of previous year mostly due to the decrease in operating expenses) in relation to the decrease of total income (decrease of 6.95% comparing to the same period of previous year due to the decrease in operating income).

Operative earnings amount to HRK 15.6 million and are by HRK 3.5 million, which is 29.27% higher comparing to the same period of previous year. Higher operative earnings are result of greater decrease of operating expenses (decrease of 7.45% comparing to the same period of previous year) in relation to the decrease of operating income (decrease of 7.03% comparing to the same period of previous year).

Realised net profit amounts to HRK 12.8 million.

Transactions with the related parties in the first three months of 2021 generated total net revenues in amount of HRK 98.7 million, which is 2.22% lower of generated revenue in the same period of previous year when it amounted to HRK 100.9 million. Decrease is a result of decrease sales in Prima Pharma Group.

Trade goods purchased from the related parties amount to HRK 37.3 million, while in the same period of previous year amounted to HRK 47.5 million, which is decrease of HRK 10.2 million, which is 21.59%.

Total assets amount to HRK 2 billion 709.2 million which is by 12.77% higher comparing to the beginning of the year.

Long term assets did not significantly change compared to the beginning of the year. Non-current intangible assets amount to HRK 39.7 million and they increased by 8.99% compared to the beginning of the year due to the inclusion of new storage space in non-current assets. Non-current tangible assets amount to HRK 156.5 million and did not significantly change compared to the beginning of the year.

Long term financial assets mostly relate to the investment in related parties and in smaller part to the given loans. Long term financial assets amount to HRK 108.5 million and are lower for 1.23% compared to the beginning of the year.

Non-current receivables refer to the given commodity loans (commodity loans are due receivables that are reprogrammed and the payment has been agreed in the future periods). Non-current receivables decreased by 9.92% compared to the beginning of the year, due to loan repayment.

Deferred tax assets are at the same level comparing to the beginning of the year.

Short term assets amount to HRK 2 billion 400.8 million which is 14.52% higher compared to the beginning of the year. In the structure of short term receivables and financial assets i have increased, while cash in bank and on hand and inventory have decreased compared to the beginning of the year.

Inventory amounts to HRK 325.0 million and has decreased by HRK 11.6 million comparing to the beginning of the year, which is 3.46%, due to lower procurement affected by decrease in sales.

Total short term receivables amount to HRK 2 billion 44.5 million and are higher for HRK 362.9 million, which is 21.58%, comparing to the beginning of the year. Trade receivables, receivables from related parties and receivables from participating parties amount to HRK 2 billion 38.8 million and have increased by 21.83% comparing to the beginning of the year due to slower collection .

Cash in bank and on hand amounts to HRK 26.0 million and decreased for HRK 47.0 million comparing to the beginning of the year.

Long term liabilities amount to HRK 79.4 million, out of which HRK 5.8 million relate to finance lease liabilities, HRK 8.5 million to liabilities based on operating lease agreement (in accordance with IFRS 16 Leases) and HRK 65.0 million to liabilities for long-term loan. Long term liabilities are higher for HRK 67.3 million comparing to the beginning of the year which was significantly affected by the change in maturity of part of short-term loans in the amount of HRK 65.0 million.

Short term liabilities amount to HRK 2 billion 162.2 million out of which the biggest part in amount of HRK 1 billion 701.3 million relates to trade payables and liabilities to related parties and HRK 422.5 million to indebtedness (HRK 418.3 million to short term loans and HRK 4.2 million to finance lease).

Trade payables and liabilities to related parties are higher for HRK 85.7 million comparing to the beginning of the year, which is 5.31%.

Total loans liabilities of Medika amounts to HRK 483.3 million which is an increase of HRK 205.0 million comparing to the beginning of the year, for the liquidity purposes. Of the total indebtedness, on 31 March 2021, HRK 65.0 million relates to long-term loan. All loans are in HRK, and there is no currency risk exposure on these items.

#### ***Key events***

Total pharmaceutical market in the first three months of 2021 has decreased comparing to the same period of previous year. At the same time, sales of Medika have decreased slightly more which affected a slightly decrease in the market share.

Total indebtedness has increased for HRK 205.0 million compared to the beginning of the year, for the liquidity purposes.

#### ***Expected future development of the Company***

The Company will continue with its core business: distribution of medicinal products and medical devices will strongly develop operations with products that make the core business of the Company.

#### ***Treasury shares***

As at 31.03.2021, the Company holds 2,940 treasury shares.

#### ***Subsidiaries and associates***

The Company has subsidiaries Zdravstvena ustanova Ljekarne Prima Pharme and Primus nekretnine d.o.o. Both subsidiaries are fully owned by the Company.

ZU Ljekarne Prima Pharme has 100% of ownership in subsidiaries ZU Ljekarne Delonga, ZU Ljekarne Ines Škoko, Ljekarna Zrinka Kujundžić Bubalo and associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

### ***Related parties***

The company with major voting rights, Auctor d.o.o. owns 42.41% of the Company and has 46.99% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 28.05% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

### ***Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk***

Within financial risks, foreign exchange risk is significant. The Company realizes majority of its revenue on domestic market in Croatian kuna. The Company's purchase of goods is partly realised on the foreign market. The Company is therefore exposed to foreign exchange risk arising from various changes in foreign exchange rates mainly linked to the EUR. All borrowings are in Croatian kuna so the Company is not exposed to foreign exchange risk from this part.

The Company has part of assets which are interest-bearing so the Company's income and operating cash flows are dependent of changes in market interest rates.

The Company's interest rate risk arises from short term and long term given loans and borrowings with variable interest rates. Borrowings with variable interest rates expose the Company to cash flow interest rate risk. Borrowings with fixed interest rates expose the Company to the fair value interest rate risk exposure.

The Company does not use derivative instruments to actively hedge cash flow and fair value interest rate risk exposure. However, the Company continuously monitors changes in interest rates. Various scenarios are simulated taking into account refinancing, renewal of existing positions and alternative financing.

Price risk arises from a continuous decrease in the price of HZZO's List of medicinal products and administrative approach in determining prices and margins of medicinal products. To lower this risk, the Company focused on increase of variety of products which are not limited by law in respect of the price of the product.


Majority of the credit risk relates to trade receivables. Credit risk is higher when dealing with private owned pharmacies. However, hospital have longer collection period, but there is no risk of unpayment.

The most significant risk within market risks is a long collection period of receivables, especially HZZO and HZZO related receivables. Therefore, a significant amount of working capital is not available what has an influence on cash flows and timely settlement of Medika liabilities.

As these receivables are directly or indirectly related to the receivables from the State institutions, the collection of these receivables should not be classified as a collection of receivables risk. This increases the need for additional financing, which increases finance expenses.

The epidemic caused by the Covid-19 virus, which appeared in Croatia in March 2020, did not have significant impact on the operations of the Company, in 2020 and in the first three months of 2020, and Company did not use support provided by the Republic of Croatia to companies whose business was therefore compromised.

<sup>3</sup> **Medika** d.d.  
ZAGREB, Capraška 1



Jasminko Herceg, dipl.oec.  
*President of the Management Board*

## Annex 1

## ISSUER'S GENERAL DATA

Reporting period:

1.1.2021

to

31.3.2021

Year:

2021

Quarter:

1.

## Quarterly financial statements

Registration number (MB):

03209741

Issuer's home Member

State code:

HR

Entity's registration

number (MBS):

080027531

Personal identification

number (OIB):

94818858923

LEI:

747800000R8ZVGJJO27

Institution

code:

1339

Name of the issuer: **MEDIKA d.d.**

Postcode and town:

10000

ZAGREB

Street and house number: **CAPRAŠKA 1**E-mail address: **medika.uprava@medika.hr**Web address: **www.medika.hr**

Number of employees

(end of the reporting

496

Consolidated report:

KN

(KN-not consolidated/KD-consolidated)

Audited:

RN

(RN-not audited/RD-audited)

Names of subsidiaries (according to IFRS):

Registered office:

MB:

Bookkeeping firm:

(Yes/No)

(name of the bookkeeping firm)

Contact person: **DIJANA RADMILOVIĆ**

(only name and surname of the contact person)

Telephone: **01/2412 551**E-mail address: **medika.uprava@medika.hr**

Audit firm:

(name of the audit firm)

Certified auditor:

(name and surname)

**BALANCE SHEET**  
balance as at 31.03.2021

in HRK

Submitter: Medika d.d.			
Item	ADP code	Last day of the preceding business year	At the reporting date of the current period
1	2	3	4
<b>A) RECEIVABLES FOR SUBSCRIBED CAPITAL UNPAID</b>	<b>001</b>	0	0
<b>B) FIXED ASSETS (ADP 003+010+020+031+036)</b>	<b>002</b>	<b>305.000.489</b>	<b>306.647.950</b>
<b>I INTANGIBLE ASSETS (ADP 004 to 009)</b>	<b>003</b>	<b>36.464.639</b>	<b>39.741.890</b>
1 Research and development	004	0	0
2 Concessions, patents, licences, trademarks, software and other rights	005	24.010.403	26.932.243
3 Goodwill	006	11.929.586	11.929.586
4 Advances for the purchase of intangible assets	007	374.082	374.082
5 Intangible assets in preparation	008	150.568	505.979
6 Other intangible assets	009	0	0
<b>II TANGIBLE ASSETS (ADP 011 to 019)</b>	<b>010</b>	<b>156.645.918</b>	<b>156.526.451</b>
1 Land	011	23.406.270	23.406.270
2 Buildings	012	107.675.773	106.572.819
3 Plant and equipment	013	18.839.578	21.570.311
4 Tools, working inventory and transportation assets	014	2.576.429	2.187.032
5 Biological assets	015	0	0
6 Advances for the purchase of tangible assets	016	31.000	0
7 Tangible assets in preparation	017	3.271.048	1.946.324
8 Other tangible assets	018	845.820	843.695
9 Investment property	019	0	0
<b>III FIXED FINANCIAL ASSETS (ADP 021 to 030)</b>	<b>020</b>	<b>109.837.493</b>	<b>108.489.411</b>
1 Investments in holdings (shares) of undertakings within the group	021	100.199.330	100.199.330
2 Investments in other securities of undertakings within the group	022	0	0
3 Loans, deposits, etc. to undertakings within the group	023	0	0
4. Investments in holdings (shares) of companies linked by virtue of participating interests	024	0	0
5 Investment in other securities of companies linked by virtue of participating interests	025	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	026	0	0
7 Investments in securities	027	0	0
8 Loans, deposits, etc. given	028	9.638.163	8.290.081
9 Other investments accounted for using the equity method	029	0	0
10 Other fixed financial assets	030	0	0
<b>IV RECEIVABLES (ADP 032 to 035)</b>	<b>031</b>	<b>1.635.092</b>	<b>1.472.851</b>
1 Receivables from undertakings within the group	032	0	0
2 Receivables from companies linked by virtue of participating interests	033	0	0
3 Customer receivables	034	1.635.092	1.472.851
4 Other receivables	035	0	0
<b>V DEFERRED TAX ASSETS</b>	<b>036</b>	<b>417.347</b>	<b>417.347</b>
<b>C) CURRENT ASSETS (ADP 038+046+053+063)</b>	<b>037</b>	<b>2.096.516.668</b>	<b>2.400.829.707</b>
<b>I INVENTORIES (ADP 039 to 045)</b>	<b>038</b>	<b>336.643.083</b>	<b>325.006.116</b>
1 Raw materials and consumables	039	119.297	126.147
2 Work in progress	040	0	0
3 Finished goods	041	0	0
4 Merchandise	042	333.880.976	323.144.291
5 Advances for inventories	043	2.642.810	1.735.678
6 Fixed assets held for sale	044	0	0
7 Biological assets	045	0	0
<b>II RECEIVABLES (ADP 047 to 052)</b>	<b>046</b>	<b>1.681.671.971</b>	<b>2.044.538.739</b>



1 Receivables from undertakings within the group	047	117.833.029	164.967.110
2 Receivables from companies linked by virtue of participating interests	048	23.720.641	33.714.042
3 Customer receivables	049	1.531.867.678	1.840.082.253
4 Receivables from employees and members of the undertaking	050	29.313	41.092
5 Receivables from government and other institutions	051	5.339.555	3.580.563
6 Other receivables	052	2.881.755	2.153.679
<b>III CURRENT FINANCIAL ASSETS (ADP 054 to 062)</b>	<b>053</b>	<b>5.120.821</b>	<b>5.238.771</b>
1 Investments in holdings (shares) of undertakings within the group	054	0	0
2 Investments in other securities of undertakings within the group	055	0	0
3 Loans, deposits, etc. to undertakings within the group	056	50.000	50.000
4 Investments in holdings (shares) of companies linked by virtue of participating interests	057	0	0
5 Investment in other securities of companies linked by virtue of participating interests	058	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	059	0	0
7 Investments in securities	060	0	0
8 Loans, deposits, etc. given	061	5.070.821	5.188.771
9 Other financial assets	062	0	0
<b>IV CASH AT BANK AND IN HAND</b>	<b>063</b>	<b>73.080.793</b>	<b>26.046.081</b>
<b>D ) PREPAID EXPENSES AND ACCRUED INCOME</b>	<b>064</b>	<b>859.895</b>	<b>1.723.068</b>
<b>E) TOTAL ASSETS (ADP 001+002+037+064)</b>	<b>065</b>	<b>2.402.377.052</b>	<b>2.709.200.725</b>
<b>OFF-BALANCE SHEET ITEMS</b>	<b>066</b>	<b>146.642.127</b>	<b>138.887.225</b>
<b>LIABILITIES</b>			
<b>A) CAPITAL AND RESERVES (ADP 068 to</b>	<b>067</b>	<b>451.783.230</b>	<b>465.633.260</b>
<b>I INITIAL (SUBSCRIBED) CAPITAL</b>	<b>068</b>	<b>209.244.420</b>	<b>209.244.420</b>
<b>II CAPITAL RESERVES</b>	<b>069</b>	<b>-7.657.921</b>	<b>-7.657.921</b>
<b>III RESERVES FROM PROFIT (ADP 071+072-073+074+075)</b>	<b>070</b>	<b>61.886.379</b>	<b>61.886.379</b>
1 Legal reserves	071	18.548.510	18.548.510
2 Reserves for treasury shares	072	48.811.980	48.811.980
3 Treasury shares and holdings (deductible item)	073	-37.187.824	-37.187.824
4 Statutory reserves	074	0	0
5 Other reserves	075	31.713.713	31.713.713
<b>IV REVALUATION RESERVES</b>	<b>076</b>	<b>0</b>	<b>0</b>
<b>V FAIR VALUE RESERVES AND OTHER (ADP 078 to 082)</b>	<b>077</b>	<b>0</b>	<b>0</b>
1 Financial assets at fair value through other comprehensive income (i.e. available for sale)	078	0	0
2 Cash flow hedge - effective portion	079	0	0
3 Hedge of a net investment in a foreign operation - effective portion	080	0	0
4 Other fair value reserves	081	0	0
5 Exchange differences arising from the translation of foreign operations (consolidation)	082	0	0
<b>VI RETAINED PROFIT OR LOSS BROUGHT FORWARD (ADP 084-085)</b>	<b>083</b>	<b>127.594.797</b>	<b>189.369.295</b>
1 Retained profit	084	127.594.797	189.369.295
2 Loss brought forward	085	0	0
<b>VII PROFIT OR LOSS FOR THE BUSINESS YEAR (ADP 087-088)</b>	<b>086</b>	<b>60.715.555</b>	<b>12.791.087</b>
1 Profit for the business year	087	60.715.555	12.791.087
2 Loss for the business year	088	0	0
<b>VIII MINORITY (NON-CONTROLLING) INTEREST</b>	<b>089</b>	<b>0</b>	<b>0</b>
<b>B) PROVISIONS (ADP 091 to 096)</b>	<b>090</b>	<b>961.788</b>	<b>961.788</b>
1 Provisions for pensions, termination benefits and similar obligations	091	961.788	961.788
2 Provisions for tax liabilities	092	0	0
3 Provisions for ongoing legal cases	093	0	0
4 Provisions for renewal of natural resources	094	0	0
5 Provisions for warranty obligations	095	0	0
6 Other provisions	096	0	0

<b>C) LONG-TERM LIABILITIES (ADP 098 to 108)</b>	<b>097</b>	<b>12.122.732</b>	<b>79.386.824</b>
1 Liabilities to undertakings within the group	098	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	099	0	0
3 Liabilities to companies linked by virtue of participating interests	100	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	101	0	0
5 Liabilities for loans, deposits etc.	102	0	0
6 Liabilities to banks and other financial institutions	103	5.823.431	70.853.221
7 Liabilities for advance payments	104	0	0
8 Liabilities to suppliers	105	0	0
9 Liabilities for securities	106	0	0
10 Other long-term liabilities	107	6.299.301	8.533.603
11 Deferred tax liability	108	0	0
<b>D) SHORT-TERM LIABILITIES (ADP 110 to 123)</b>	<b>109</b>	<b>1.936.250.525</b>	<b>2.162.162.318</b>
1 Liabilities to undertakings within the group	110	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	111	0	0
3 Liabilities to companies linked by virtue of participating interests	112	64.034.757	82.311.650
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	113	0	0
5 Liabilities for loans, deposits etc.	114	0	0
6 Liabilities to banks and other financial institutions	115	282.534.541	422.506.019
7 Liabilities for advance payments	116	2.343.096	16.304
8 Liabilities to suppliers	117	1.551.504.994	1.618.952.575
9 Liabilities for securities	118	0	0
10 Liabilities to employees	119	8.332.383	6.177.786
11 Taxes, contributions and similar liabilities	120	25.149.842	28.877.684
12 Liabilities arising from the share in the result	121	0	0
13 Liabilities arising from fixed assets held for sale	122	0	0
14 Other short-term liabilities	123	2.350.912	3.320.300
<b>E) ACCRUALS AND DEFERRED INCOME</b>	<b>124</b>	<b>1.258.777</b>	<b>1.056.535</b>
<b>F) TOTAL – LIABILITIES (ADP 067+090+097+109+124)</b>	<b>125</b>	<b>2.402.377.052</b>	<b>2.709.200.725</b>
<b>G) OFF-BALANCE SHEET ITEMS</b>	<b>126</b>	<b>146.642.127</b>	<b>138.887.225</b>

**STATEMENT OF PROFIT OR LOSS**  
for the period 01.01.2021 to 31.03.2021

in HRK

Submitter: Medika d.d.

Item	ADP code	Same period of the previous year		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
<b>I OPERATING INCOME (ADP 002 to 006)</b>	<b>001</b>	<b>1.049.482.483</b>	<b>1.049.482.483</b>	<b>975.675.077</b>	<b>975.675.077</b>
1 Income from sales with undertakings within the group	002	85.646.225	85.646.225	82.854.825	82.854.825
2 Income from sales (outside group)	003	959.508.534	959.508.534	889.519.866	889.519.866
3 Income from the use of own products, goods and services	004	0	0	0	0
4 Other operating income with undertakings within the group	005	130.226	130.226	146.072	146.072
5 Other operating income (outside the group)	006	4.197.498	4.197.498	3.154.314	3.154.314
<b>II OPERATING EXPENSES (ADP 008+009+013+017+018+019+022+029)</b>	<b>007</b>	<b>1.037.425.241</b>	<b>1.037.425.241</b>	<b>960.089.058</b>	<b>960.089.058</b>
1 Changes in inventories of work in progress and finished goods	008	0	0	0	0
2 Material costs (ADP 010 to 012)	009	997.797.859	997.797.859	932.369.317	932.369.317
a) Costs of raw materials and consumables	010	3.051.482	3.051.482	2.667.307	2.667.307
b) Costs of goods sold	011	990.375.819	990.375.819	925.356.295	925.356.295
c) Other external costs	012	4.370.558	4.370.558	4.345.715	4.345.715
3 Staff costs (ADP 014 to 016)	013	17.834.440	17.834.440	16.242.846	16.242.846
a) Net salaries and wages	014	10.798.320	10.798.320	10.187.625	10.187.625
b) Tax and contributions from salary costs	015	4.646.858	4.646.858	3.888.479	3.888.479
c) Contributions on salaries	016	2.389.262	2.389.262	2.166.742	2.166.742
4 Depreciation	017	3.726.823	3.726.823	4.148.982	4.148.982
5 Other costs	018	19.463.597	19.463.597	7.280.550	7.280.550
6 Value adjustments (ADP 020+021)	019	-598.080	-598.080	47.363	47.363
a) fixed assets other than financial assets	020	0	0	0	0
b) current assets other than financial assets	021	-598.080	-598.080	47.363	47.363
7 Provisions (ADP 023 to 028)	022	-799.398	-799.398	0	0
a) Provisions for pensions, termination benefits and similar obligations	023	0	0	0	0
b) Provisions for tax liabilities	024	0	0	0	0
c) Provisions for ongoing legal cases	025	-799.398	-799.398	0	0
d) Provisions for renewal of natural resources	026	0	0	0	0
e) Provisions for warranty obligations	027	0	0	0	0
f) Other provisions	028	0	0	0	0
8 Other operating expenses	029	0	0	0	0
<b>III FINANCIAL INCOME (ADP 031 to 040)</b>	<b>030</b>	<b>537.936</b>	<b>537.936</b>	<b>1.380.302</b>	<b>1.380.302</b>
1 Income from investments in holdings (shares) of undertakings within the group	031	0	0	0	0
2 Income from investments in holdings (shares) of companies linked by virtue of participating interests	032	0	0	0	0
3 Income from other long-term financial investment and loans granted to undertakings within the group	033	0	0	0	0
4 Other interest income from operations with undertakings within the group	034	294	294	370	370
5 Exchange rate differences and other financial income from operations with undertakings within the group	035	0	0	0	0
6 Income from other long-term financial investments and loans	036	0	0	0	0
7 Other interest income	037	537.642	537.642	1.379.932	1.379.932
8 Exchange rate differences and other financial income	038	0	0	0	0
9 Unrealised gains (income) from financial assets	039	0	0	0	0
10 Other financial income	040	0	0	0	0
<b>IV FINANCIAL EXPENSES (ADP 042 to 048)</b>	<b>041</b>	<b>1.463.025</b>	<b>1.463.025</b>	<b>1.367.435</b>	<b>1.367.435</b>
1 Interest expenses and similar expenses with undertakings within the group	042	0	0	0	0
2 Exchange rate differences and other expenses from operations with undertakings within the group	043	0	0	0	0
3 Interest expenses and similar expenses	044	1.169.584	1.169.584	1.268.775	1.268.775
4 Exchange rate differences and other expenses	045	293.441	293.441	98.660	98.660
5 Unrealised losses (expenses) from financial assets	046	0	0	0	0
6 Value adjustments of financial assets (net)	047	0	0	0	0
7 Other financial expenses	048	0	0	0	0
<b>V SHARE IN PROFIT FROM UNDERTAKINGS LINKED BY VIRTUE OF PARTICIPATING INTERESTS</b>	<b>049</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VI SHARE IN PROFIT FROM JOINT VENTURES</b>	<b>050</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VII SHARE IN LOSS OF COMPANIES LINKED BY VIRTUE OF PARTICIPATING INTEREST</b>	<b>051</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VIII SHARE IN LOSS OF JOINT VENTURES</b>	<b>052</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>IX TOTAL INCOME (ADP 001+030+049 +050)</b>	<b>053</b>	<b>1.050.020.419</b>	<b>1.050.020.419</b>	<b>977.055.379</b>	<b>977.055.379</b>
<b>X TOTAL EXPENDITURE (ADP 007+041+051 + 052)</b>	<b>054</b>	<b>1.038.888.266</b>	<b>1.038.888.266</b>	<b>961.456.493</b>	<b>961.456.493</b>
<b>XI PRE-TAX PROFIT OR LOSS (ADP 053-054)</b>	<b>055</b>	<b>11.132.153</b>	<b>11.132.153</b>	<b>15.598.886</b>	<b>15.598.886</b>
1 Pre-tax profit (ADP 053-054)	056	11.132.153	11.132.153	15.598.886	15.598.886

2 Pre-tax loss (ADP 054-053)	057	0	0	0	0
<b>XII INCOME TAX</b>	<b>058</b>	<b>2,003,788</b>	<b>2,003,788</b>	<b>2,807,799</b>	<b>2,807,799</b>
<b>XIII PROFIT OR LOSS FOR THE PERIOD (ADP 055-059)</b>	<b>059</b>	<b>9,128,365</b>	<b>9,128,365</b>	<b>12,791,087</b>	<b>12,791,087</b>
1 Profit for the period (ADP 055-059)	060	9,128,365	9,128,365	12,791,087	12,791,087
2 Loss for the period (ADP 059-055)	061	0	0	0	0
<b>DISCONTINUED OPERATIONS (to be filled in by undertakings subject to IFRS only with discontinued operations)</b>					
<b>XIV PRE-TAX PROFIT OR LOSS OF DISCONTINUED OPERATIONS (ADP 063-064)</b>	<b>062</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Pre-tax profit from discontinued operations	063	0	0	0	0
2 Pre-tax loss on discontinued operations	064	0	0	0	0
<b>XV INCOME TAX OF DISCONTINUED OPERATIONS</b>	<b>065</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Discontinued operations profit for the period (ADP 062-065)	066	0	0	0	0
2 Discontinued operations loss for the period (ADP 065-062)	067	0	0	0	0
<b>TOTAL OPERATIONS (to be filled in only by undertakings subject to IFRS with discontinued operations)</b>					
<b>XVI PRE-TAX PROFIT OR LOSS (ADP 055-+062)</b>	<b>068</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Pre-tax profit (ADP 068)	069	0	0	0	0
2 Pre-tax loss (ADP 068)	070	0	0	0	0
<b>XVII INCOME TAX (ADP 058+065)</b>	<b>071</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>XVIII PROFIT OR LOSS FOR THE PERIOD (ADP 068-071)</b>	<b>072</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Profit for the period (ADP 068-071)	073	0	0	0	0
2 Loss for the period (ADP 071-068)	074	0	0	0	0
<b>APPENDIX to the P&amp;L (to be filled in by undertakings that draw up consolidated annual financial statements)</b>					
<b>XIX PROFIT OR LOSS FOR THE PERIOD (ADP 076+077)</b>	<b>075</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Attributable to owners of the parent	076	0	0	0	0
2 Attributable to minority (non-controlling) interest	077	0	0	0	0
<b>STATEMENT OF OTHER COMPREHENSIVE INCOME (to be filled in by undertakings subject to IFRS)</b>					
<b>I PROFIT OR LOSS FOR THE PERIOD</b>	<b>078</b>	<b>9,128,365</b>	<b>9,128,365</b>	<b>12,791,087</b>	<b>12,791,087</b>
<b>II OTHER COMPREHENSIVE INCOME/LOSS BEFORE TAX (ADP 80+ 87)</b>	<b>079</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>III Items that will not be reclassified to profit or loss (ADP 081 to 085)</b>	<b>080</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Changes in revaluation reserves of fixed tangible and intangible assets	081	0	0	0	0
2 Gains or losses from subsequent measurement of equity instruments at fair value through other comprehensive income	082	0	0	0	0
3 Fair value changes of financial liabilities at fair value through statement of profit or loss, attributable to changes in their credit risk	083	0	0	0	0
4 Actuarial gains/losses on the defined benefit obligation	084	0	0	0	0
5 Other items that will not be reclassified	085	0	0	0	0
6 Income tax relating to items that will not be reclassified	086	0	0	0	0
<b>IV Items that may be reclassified to profit or loss (ADP 088 to 095)</b>	<b>087</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Exchange rate differences from translation of foreign operations	088	0	0	0	0
2 Gains or losses from subsequent measurement of debt securities at fair value through other comprehensive income	089	0	0	0	0
3 Profit or loss arising from effective cash flow hedging	090	0	0	0	0
4 Profit or loss arising from effective hedge of a net investment in a foreign operation	091	0	0	0	0
5 Share in other comprehensive income/loss of companies linked by virtue of participating interests	092	0	0	0	0
6 Changes in fair value of the time value of option	093	0	0	0	0
7 Changes in fair value of forward elements of forward contracts	094	0	0	0	0
8 Other items that may be reclassified to profit or loss	095	0	0	0	0
9 Income tax relating to items that may be reclassified to profit or loss	096	0	0	0	0
<b>V NET OTHER COMPREHENSIVE INCOME OR LOSS (ADP 080+087-086 - 096)</b>	<b>097</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 078+097)</b>	<b>098</b>	<b>9,128,365</b>	<b>9,128,365</b>	<b>12,791,087</b>	<b>12,791,087</b>
<b>APPENDIX to the Statement on comprehensive income (to be filled in by undertakings that draw up consolidated statements)</b>					
<b>VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 100+101)</b>	<b>099</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Attributable to owners of the parent	100	0	0	0	0
2 Attributable to minority (non-controlling) interest	101	0	0	0	0

**STATEMENT OF CASH FLOWS - indirect method**  
for the period 01.01.2021 to 31.03.2021

in HRK

Submitter: Medika d.d.			
Item	ADP code	Same period of the previous year	Current period
1	2	3	4
<b>Cash flow from operating activities</b>			
1 Pre-tax profit	001	11.132.153	15.598.886
2 Adjustments (ADP 003 to 010):	002	15.652.238	6.231.021
a) Depreciation	003	3.726.823	4.148.982
b) Gains and losses from sale and value adjustment of fixed tangible and intangible assets	004	-200.354	-465.275
c) Gains and losses from sale and unrealised gains and losses and value adjustment of financial assets	005	-598.080	47.363
d) Interest and dividend income	006	-537.936	-1.380.301
e) Interest expenses	007	1.169.584	1.268.775
f) Provisions	008	-799.398	0
g) Exchange rate differences (unrealised)	009	11.699.444	1.552.639
h) Other adjustments for non-cash transactions and unrealised gains and losses	010	1.192.155	1.058.838
<b>I Cash flow increase or decrease before changes in working capital (ADP 001+002)</b>	<b>011</b>	<b>26.784.391</b>	<b>21.829.907</b>
3 Changes in the working capital (ADP 013 to 016)	012	-45.531.931	-270.854.135
a) Increase or decrease in short-term liabilities	013	227.845.255	81.259.134
b) Increase or decrease in short-term receivables	014	-190.674.919	-363.750.236
c) Increase or decrease in inventories	015	-82.702.267	11.636.967
d) Other increase or decrease in working capital	016	0	0
<b>II Cash from operations (ADP 011+012)</b>	<b>017</b>	<b>-18.747.540</b>	<b>-249.024.228</b>
4 Interest paid	018	-1.174.658	-961.996
5 Income tax paid	019	0	-761.166
<b>A) NET CASH FLOW FROM OPERATING ACTIVITIES (ADP 017 to 019)</b>	<b>020</b>	<b>-19.922.198</b>	<b>-250.747.390</b>
<b>Cash flow from investment activities</b>			
1 Cash receipts from sales of fixed tangible and intangible assets	021	222.269	556.140
2 Cash receipts from sales of financial instruments	022	0	0
3 Interest received	023	539.419	1.375.343
4 Dividends received	024	0	0
5 Cash receipts from repayment of loans and deposits	025	2.105.954	1.609.460
6 Other cash receipts from investment activities	026	0	0
<b>III Total cash receipts from investment activities (ADP 021 to 026)</b>	<b>027</b>	<b>2.867.642</b>	<b>3.540.943</b>
1 Cash payments for the purchase of fixed tangible and intangible assets	028	-923.315	-2.958.272
2 Cash payments for the acquisition of financial instruments	029	0	0
3 Cash payments for loans and deposits for the period	030	-50.000	0
4 Acquisition of a subsidiary, net of cash acquired	031	0	0
5 Other cash payments from investment activities	032	0	0
<b>IV Total cash payments from investment activities (ADP 028 to 032)</b>	<b>033</b>	<b>-973.315</b>	<b>-2.958.272</b>
<b>B) NET CASH FLOW FROM INVESTMENT ACTIVITIES (ADP 027 +033)</b>	<b>034</b>	<b>1.894.327</b>	<b>582.671</b>
<b>Cash flow from financing activities</b>			
1 Cash receipts from the increase in initial (subscribed) capital	035	0	0
2 Cash receipts from the issue of equity financial instruments and debt financial instruments	036	0	0
3 Cash receipts from credit principals, loans and other borrowings	037	120.000.000	205.000.000
4 Other cash receipts from financing activities	038	0	0

<b>V Total cash receipts from financing activities (ADP 035 to 038)</b>	<b>039</b>	<b>120.000.000</b>	<b>205.000.000</b>
1 Cash payments for the repayment of credit principals, loans and other borrowings and debt financial instruments	<b>040</b>	-100.000.000	0
2 Cash payments for dividends	<b>041</b>	0	0
3 Cash payments for finance lease	<b>042</b>	-1.318.444	-1.226.865
4 Cash payments for the redemption of treasury shares and decrease in initial (subscribed) capital	<b>043</b>	0	0
5 Other cash payments from financing activities	<b>044</b>	-389.014	-643.128
<b>VI Total cash payments from financing activities (ADP 040 to 044)</b>	<b>045</b>	<b>-101.707.458</b>	<b>-1.869.993</b>
<b>C) NET CASH FLOW FROM FINANCING ACTIVITIES (ADP 039 +045)</b>	<b>046</b>	<b>18.292.542</b>	<b>203.130.007</b>
1 Unrealised exchange rate differences in respect of cash and cash equivalents	<b>047</b>	0	0
<b>D) NET INCREASE OR DECREASE IN CASH FLOWS (ADP 020+034+046+047)</b>	<b>048</b>	<b>264.671</b>	<b>-47.034.712</b>
<b>E) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD</b>	<b>049</b>	<b>46.307.831</b>	<b>73.080.793</b>
<b>F) CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD(ADP 048+049)</b>	<b>050</b>	<b>46.572.502</b>	<b>26.046.081</b>



FINANCIAL STATEMENT NOTES  
(are compiled for quarterly reporting periods)

Issuer: MEDIKA d.d.

OIB: 94818858923

Reporting period: 01.01.2021. - 31.03.2021.

Financial statements notes, for quarterly periods, include:

a) explanation of business events relevant to understanding changes in the statement of financial position and financial performance for the reporting quarterly period of the issuer with respect to the last business year: information is provided regarding these events and relevant information published in the last annual financial statement is updated (items 15 to 15C IAS 34 - Interim financial reporting)

The financial statements of the Medika d.d. have been prepared in accordance with International Financial Reporting Standards adopted by the European Union (IFRS). The financial statements have been prepared under the historical cost convention unless stated otherwise.

The preparation of financial statements in conformity with International Financial Reporting Standards adopted by the European Union (IFRS) requires the use of certain critical accounting estimates.

On 31 March 2021 compared to the beginning of the year Medika d.d. increased its credit indebtedness by HRK 205.0 million for current liquidity purposes.

Significant business events and transactions in the observed period, which are important for understanding the changes in the Statement of Financial Position and business results are explained in the pdf document - Interim Management Report for I-III 2021 Medika dd, which was published with this document, at the same time, on the web pages of Medika dd [www.medika.hr](http://www.medika.hr), on the website of the Zagreb Stock Exchange d.d. and was submitted to the Officially appointed mechanism for the central storage of regulated information at the Croatian Financial Services Supervisory Agency.

b) information on the access to the latest annual financial statements, for the purpose of understanding information published in the notes to financial statements drawn up for the quarterly reporting period,

The financial statement notes are attached to the audited annual financial statements of Medika d.d. The audited annual financial statements for 2020 are available on the website of Medika d.d. [www.medika.hr](http://www.medika.hr), on the website of the Zagreb Stock Exchange d.d. and was submitted to the Officially appointed mechanism for the central storage of regulated information at the Croatian Financial Services Supervisory Agency.

c) a statement explaining that the same accounting policies are applied while drawing up financial statements for the quarterly reporting period as in the latest annual financial statements or, in the case where the accounting policies have changed, a description of the nature and effect of the changes (item 16.A (a) IAS 34 - Interim financial reporting),

Medika d.d. declares that the same accounting policies are applied in the financial statements for the period 01.01.-31.03.2021. as well as in the annual financial statements for 2020.

d) a description of the financial performance in the case of the issuer whose business is seasonal (items 37 and 38 IAS 34 - Interim financial reporting)

Medika d.d. does not perform activities of a seasonal nature.

e) other comments prescribed by IAS 34 - Interim financial reporting

Long-term intangible assets amount to HRK 39.7 million and are higher by 8.99% compared to the beginning of the year due to the inclusion of new leased storage space in fixed assets.

Receivables from customers, related companies and participating companies amount to HRK 2 billion 38.8 million and increased by 21.83% compared to the beginning of the year due to slower payment collection.

Reclassification:

AOP 117 Liabilities to employees include short-term provisions.

Assets with the right of use are stated within long-term intangible assets by type of assets, while lease liabilities are stated within other long-term and short-term liabilities.

Interest payable on loans are stated within other short-term liabilities.

f) in the notes to quarterly periods financial statements, in addition to the information stated above, information in respect of the following matters shall be disclosed:

1. undertaking's name, registered office (address), legal form, country of establishment, entity's registration number (MBS), personal identification number (OIB) and, if applicable, the indication whether the undertaking is undergoing liquidation, bankruptcy proceedings, shortened termination proceedings or extraordinary administration

Name of the issuer: Medika d.d.,

Headquarters: Capraška 1, 10000 Zagreb

Legal form: joint stock company

Country of establishment: Republic of Croatia

Entity's registration number (MBS): 080027531

Personal identification number (OIB): 94818858923

2. adopted accounting policies (only an indication of whether there has been a change from the previous period)

Medika d.d., during the reporting period, did not change its accounting policies compared to the previous year.

3. the total amount of any financial commitments, guarantees or contingencies that are not included in the balance sheet, and an indication of the nature and form of any valuable security which has been provided; any commitments concerning pensions of the undertaking within the group or company linked by virtue of participating interest shall be disclosed separately

For the certain part of liabilities to suppliers and loans (which are stated in the balance sheet) Medika d.d. has issued bank guarantees or debentures as payment security instrument.

Liabilities based on pension provisions are shown in the balance sheet – IAS 19.

4. the amount and nature of individual items of income or expenditure which are of exceptional size or incidence

Medika d.d., in the reporting period 01.01.-31.03.2021, generated sales revenues in the amount of HRK 972,375 thousand (in the period 01.01.-31.03.2020. HRK 1,045,155 thousand).

5. amounts owed by the undertaking and falling due after more than five years, as well as the total debts of the undertaking covered by valuable security furnished by the undertaking, specifying the type and form of security

Medika d.d. has no liabilities that mature after 5 years.

Loan liabilities have been secured by pledges over property and equipment with a carrying amount of HRK 121,730 thousand as at 31 March 2021.



6. average number of employees during the current period

Average number of employees during the current period 01.01.-31.03.2021. is 494 employees (during the period 01.01.-31.03.2021. the average number of employees was 510 employees).

7. where, in accordance with the regulations, the undertaking capitalised on the cost of salaries in part or in full, information on the amount of the total cost of employees during the year broken down into the amount directly debiting the costs of the period and the amount capitalised on the value of the assets during the period, showing separately the total amount of net salaries and the amount of taxes, contributions from salaries and contributions on salaries  
Medika d.d. did not capitalize the cost of salaries during the reporting period.

8. where a provision for deferred tax is recognised in the balance sheet, the deferred tax balances at the end of the financial year, and the movement in those balances during the financial year

Deferred tax assets as at 31 March 2020 amounts to HRK 417 thousand and does not record a movement compared to the beginning of the year.

9. the name and registered office of each of the undertakings in which the undertaking, either itself or through a person acting in their own name but on the undertaking's behalf, holds a participating interest of capital, showing the proportion of the capital held, the amount of capital and reserves, and the profit or loss for the latest financial year of the undertaking concerned for which financial statements have been adopted; the information concerning capital and reserves and the profit or loss may be omitted where the undertaking concerned does not publish its balance sheet and is not controlled by another undertaking

Medika d.d. has 100% stakes in ZU Ljekarne Prima Pharme which holds 49% stakes in ZU Ljekarne Jagatić.

10. the number and the nominal value or, in the absence of a nominal value, the accounting par value of the shares subscribed during the financial year within the limits of the authorised capital

During the financial year there no subscribed new shares.

Share capital as at 31 March 2021 is HRK 209,244,420 and is divided into 30,194 shares. The nominal value of one share is HRK 6,930.

11. the existence of any participation certificates, convertible debentures, warrants, options or similar securities or rights, with an indication of their number and the rights they confer.

Medika d.d. has no participation certificates, convertible debentures, warrants, options or similar securities or rights.

12. the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability

Not applicable.

13. the name and registered office of the undertaking which draws up the quarterly consolidated financial statements of the largest group of undertakings of which the undertaking forms part as a controlled group member

Not applicable.

14. the name and registered office of the undertaking which draws up the quarterly consolidated financial statements of the smallest group of undertakings of which the undertaking forms part as a controlled group member and which is also included in the group of undertakings referred to in point 13

Not applicable.

15. the place where copies of the quarterly consolidated financial statements referred to in points 13 and 14 may be obtained, provided that they are available

Not applicable.

16. the nature and business purpose of the undertaking's arrangements that are not included in the balance sheet and the financial impact on the undertaking of those arrangements, provided that the risks or benefits arising from such arrangements are material and in so far as the disclosure of such risks or benefits is necessary for the purposes of assessing the financial position of the undertaking.

Medika d.d. has no material arrangements with companies that are not included in the financial statements as at 31 March 2021.

17. the nature and the financial effect of material events arising after the balance sheet date which are not reflected in the profit and loss account or balance sheet  
Medika d.d. has no significant events that occurred after the balance sheet date and are not reflected in the profit and loss account or loss or balance sheet.

Zagreb, 29 April 2021

Pursuant to the articles 462 to 471 of the Capital market Law (Official Gazette 65/18) President of the Management Board Jasminko Herceg provides

### **STATEMENT OF LIABILITY FOR PREPARING FINANCIAL STATEMENTS OF ISSUER**

Temporary unaudited unconsolidated and consolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Temporary unaudited unconsolidated and consolidated financial statements for the period 01 January to 31 March 2021 present true and fair view of assets and liabilities, financial position, profit or loss of the Company and the Group.

The interim management report for the temporary unaudited financial statements for the period 01 January to 31 March 2021 presents fair presentation of development and results of the operations and position of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.



**Medika** d.d.  
ZAGREB, Capraška 1

Jasminko Herceg  
*President of the Management Board*

